Workflow
Cara Therapeutics(CARA)
icon
Search documents
Cara Therapeutics(CARA) - 2023 Q4 - Annual Results
2024-03-03 16:00
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– STAMFORD, Conn., March 4, 2024 – Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2023. 2023 ...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Newsfilter· 2024-02-12 21:01
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Event ...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Globenewswire· 2024-02-12 21:01
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under “Even ...
Cara Therapeutics(CARA) - 2023 Q3 - Earnings Call Transcript
2023-11-14 00:20
Cara Therapeutics, Inc. (Cara) Q3 2023 Earnings Call Transcript November 13, 2023 4:30 PM ET Company Participants Matt Murphy - Manager of IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves - Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Company Sumant Kulkarni - Canaccord Genuity David Amsellem - Piper Sandler Annabel Samimy - Stifel Oren Livnat - H.C. Wainwright Operator Good afternoon. My name is Latif and I will be your conference facilitator. I would like to welco ...
Cara Therapeutics(CARA) - 2023 Q3 - Quarterly Report
2023-11-12 16:00
CARA THERAPEUTICS, INC. CONDENSED STATEMENTS OF COMPREHENSIVE LOSS (amounts in thousands, excluding share and per share data) (unaudited) Table of Contents 3 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------|-------------------|------------------|-------|----------------------------------|-------------------------|-------|------------------------------------------|------------------------------| | | Common \nShares | Stock \nAmount | | Ad ...
Cara Therapeutics(CARA) - 2023 Q2 - Earnings Call Transcript
2023-08-07 22:13
Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Matthew Murphy - Manager, IR Christopher Posner - President, CEO & Director Ryan Maynard - CFO Scott Terrillion - Chief Compliance Officer, General Counsel & Corporate Secretary Conference Call Participants Dennis Ding - Jefferies Annabel Samimy - Stifel, Nicolaus & Company Joseph Stringer - Needham & Company Sumant Kulkarni - Canaccord Genuity David Amsellem - Piper Sandler & Co. Chi Fong - ...
Cara Therapeutics(CARA) - 2023 Q2 - Quarterly Report
2023-08-06 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 COMMISSION FILE NUMBER 001-36279 CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 75-3175693 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 4 Stamford Plaza 107 Elm Street, 9 th Floor Stamford, Connecticut 06902 (A ...
Cara Therapeutics(CARA) - 2023 Q1 - Earnings Call Transcript
2023-05-15 23:31
Cara Therapeutics, Inc. (NASDAQ:CARA) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Christopher Posner - CEO Ryan Maynard - CFO Dr. Joana Goncalves - Chief Medical Officer Conference Call Participants Joseph Stringer - Needham and Company Annabel Samimy - Stifel David Amsellem - Piper Sandler Chi Fong - Bank of America Securities Sumant Kulkarni - Canaccord Genuity Operator Good afternoon. My name is Lateef, and I will be your conference facilitator. ...
Cara Therapeutics(CARA) - 2023 Q1 - Quarterly Report
2023-05-14 16:00
The Company may offer additional securities under its Shelf Registration Statement from time to time in response to market conditions or other circumstances if it believes such a plan of financing is in the best interests of its stockholders. In October 2020, the Company entered into a license agreement with Vifor International, or Vifor Agreement No. 1, under which the Company granted Vifor International an exclusive license solely in the United States to use, distribute, offer for sale, promote, sell and ...
Cara Therapeutics(CARA) - 2022 Q4 - Earnings Call Transcript
2023-03-07 01:44
Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2022 Results Conference Call March 6, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Dr. Joana Goncalves - Chief Medical Officer Conference Call Participants Sumant Kulkarni - Canaccord Genuity Joseph Stringer - Needham and Company Annabel Samimy - Stifel David Amsellem - Piper Sandler AJ Velasquez-Mao - Jefferies Oren Livnat - H.C. Wainwright Jason Gerberry - Bank of America Oren Livnat - H.C. Wainwright Sumant K ...